Making botulinum toxin treatments safer and more effective
Biology and Engineering of Botulinum Neurotoxins.
This project develops improved botulinum-toxin-based therapies for conditions like overactive bladder and new antibody-based protections for people exposed to botulinum toxins.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11143199 on NIH RePORTER |
What this research studies
From a patient perspective, the team is redesigning botulinum toxin proteins so they latch onto the nerve types that control autonomic and sensory functions, with the goal of improving benefit for conditions such as overactive bladder. They will test these engineered toxins in rodent models to see if they work better than standard Botox. In parallel, researchers are making a new kind of antibody-like molecule (three linked nanobodies fused to an Fc) meant to mop up and clear botulinum toxins from the bloodstream. These lab and animal studies aim to create therapies that could move to human testing after safety and efficacy are demonstrated.
Who could benefit from this research
Good fit: People with conditions currently treated by botulinum toxins—for example patients with overactive bladder—or individuals who might enroll in future clinical trials of new antidotes are the most relevant candidates.
Not a fit: People without neuromuscular or autonomic conditions treated by BoNTs, or those looking only for cosmetic wrinkle treatments, are unlikely to get direct benefit from this early-stage research.
Why it matters
Potential benefit: If successful, this work could produce Botox-like treatments that relieve conditions such as overactive bladder more effectively and durable antibody therapies that protect or treat people exposed to botulinum toxin.
How similar studies have performed: Botulinum products like Botox are already established for several medical uses, and early laboratory studies support engineered toxins and nanobody neutralizers, but the specific engineered approaches here remain experimental.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Dong, Min — Boston Children's Hospital
- Study coordinator: Dong, Min
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.